Ularitide is a synthetic form of urodilatin, a naturally occurring human natriuretic peptide that is involved in regulating blood pressure and the excretion of water and sodium from the kidneys. Urodilatin is produced in the kidney and excreted into the urine, and thus exists in low levels naturally in the systemic blood circulation. When injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation.
Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Sodium phosphate, monobasic | Ularitide may increase the nephrotoxic activities of Sodium phosphate, monobasic. |
| Acemetacin | The therapeutic efficacy of Ularitide can be decreased when used in combination with Acemetacin. |
| Lactulose | The risk or severity of dehydration can be increased when Ularitide is combined with Lactulose. |
| Magnesium sulfate | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium sulfate. |
| Mannitol | The risk or severity of dehydration can be increased when Ularitide is combined with Mannitol. |
| Lubiprostone | The risk or severity of dehydration can be increased when Ularitide is combined with Lubiprostone. |
| Tegaserod | The risk or severity of dehydration can be increased when Ularitide is combined with Tegaserod. |
| Magnesium oxide | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium oxide. |
| Magnesium cation | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium cation. |
| Sorbitol | The risk or severity of dehydration can be increased when Ularitide is combined with Sorbitol. |
| Dantron | The risk or severity of dehydration can be increased when Ularitide is combined with Dantron. |
| Oxyphenisatin | The risk or severity of dehydration can be increased when Ularitide is combined with Oxyphenisatin. |
| Phenolphthalein | The risk or severity of dehydration can be increased when Ularitide is combined with Phenolphthalein. |
| Prucalopride | The risk or severity of dehydration can be increased when Ularitide is combined with Prucalopride. |
| Emodin | The risk or severity of dehydration can be increased when Ularitide is combined with Emodin. |
| Linaclotide | The risk or severity of dehydration can be increased when Ularitide is combined with Linaclotide. |
| Bisacodyl | The risk or severity of dehydration can be increased when Ularitide is combined with Bisacodyl. |
| Magnesium hydroxide | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium hydroxide. |
| Bisoxatin | The risk or severity of dehydration can be increased when Ularitide is combined with Bisoxatin. |
| Picosulfuric acid | The risk or severity of dehydration can be increased when Ularitide is combined with Picosulfuric acid. |
| Magnesium trisilicate | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium trisilicate. |
| Polyethylene glycol | The risk or severity of dehydration can be increased when Ularitide is combined with Polyethylene glycol. |
| Polycarbophil | The risk or severity of dehydration can be increased when Ularitide is combined with Polycarbophil. |
| Magnesium acetate tetrahydrate | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium acetate tetrahydrate. |
| Monopotassium phosphate | The risk or severity of dehydration can be increased when Ularitide is combined with Monopotassium phosphate. |
| Dipotassium phosphate | The risk or severity of dehydration can be increased when Ularitide is combined with Dipotassium phosphate. |
| Glycerin | The risk or severity of dehydration can be increased when Ularitide is combined with Glycerin. |
| Sodium sulfate | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium sulfate. |
| Magnesium carbonate | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium carbonate. |
| Potassium lactate | The risk or severity of dehydration can be increased when Ularitide is combined with Potassium lactate. |
| Sodium fluorophosphate | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium fluorophosphate. |
| Mineral oil | The risk or severity of dehydration can be increased when Ularitide is combined with Mineral oil. |
| Carboxymethylcellulose | The risk or severity of dehydration can be increased when Ularitide is combined with Carboxymethylcellulose. |
| Docusate | The risk or severity of dehydration can be increased when Ularitide is combined with Docusate. |
| Plantago seed | The risk or severity of dehydration can be increased when Ularitide is combined with Plantago seed. |
| Magnesium citrate | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium citrate. |
| Castor oil | The risk or severity of dehydration can be increased when Ularitide is combined with Castor oil. |
| Magnesium glycinate | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium glycinate. |
| Methylcellulose | The risk or severity of dehydration can be increased when Ularitide is combined with Methylcellulose. |
| Sennosides | The risk or severity of dehydration can be increased when Ularitide is combined with Sennosides. |
| Lactitol | The risk or severity of dehydration can be increased when Ularitide is combined with Lactitol. |
| Plecanatide | The risk or severity of dehydration can be increased when Ularitide is combined with Plecanatide. |
| Gluconic Acid | The risk or severity of dehydration can be increased when Ularitide is combined with Gluconic Acid. |
| Magnesium peroxide | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium peroxide. |
| Pentaerithrityl | The risk or severity of dehydration can be increased when Ularitide is combined with Pentaerithrityl. |
| Sodium tartrate | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium tartrate. |
| Magnesium acetate | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium acetate. |
| Deacetylbisacodyl | The risk or severity of dehydration can be increased when Ularitide is combined with Deacetylbisacodyl. |
| Sodium ascorbate | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium ascorbate. |
| Potassium sulfate | The risk or severity of dehydration can be increased when Ularitide is combined with Potassium sulfate. |
| Sodium phosphate, dibasic | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium phosphate, dibasic. |
| Sodium phosphate, monobasic, unspecified form | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium phosphate, monobasic, unspecified form. |
| Sodium phosphate, dibasic, unspecified form | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium phosphate, dibasic, unspecified form. |
| Magnesium | The risk or severity of dehydration can be increased when Ularitide is combined with Magnesium. |
| Sodium cation | The risk or severity of dehydration can be increased when Ularitide is combined with Sodium cation. |
| Plantago ovata seed | The risk or severity of dehydration can be increased when Ularitide is combined with Plantago ovata seed. |
| Oxyphenisatin acetate | The risk or severity of dehydration can be increased when Ularitide is combined with Oxyphenisatin acetate. |
| Calcium polycarbophil | The risk or severity of dehydration can be increased when Ularitide is combined with Calcium polycarbophil. |
| Konjac mannan | The risk or severity of dehydration can be increased when Ularitide is combined with Konjac mannan. |
| Alloin | The risk or severity of dehydration can be increased when Ularitide is combined with Alloin. |
| Frangula purshiana bark | The risk or severity of dehydration can be increased when Ularitide is combined with Frangula purshiana bark. |
| Dehydrocholic acid | The risk or severity of dehydration can be increased when Ularitide is combined with Dehydrocholic acid. |
| Sulfate ion | The risk or severity of dehydration can be increased when Ularitide is combined with Sulfate ion. |
| Diflunisal | Ularitide may increase the excretion rate of Diflunisal which could result in a lower serum level and potentially a reduction in efficacy. |
| Ibuprofen | Ularitide may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy. |
| Naloxone | Ularitide may increase the excretion rate of Naloxone which could result in a lower serum level and potentially a reduction in efficacy. |
| Dexketoprofen | Ularitide may increase the excretion rate of Dexketoprofen which could result in a lower serum level and potentially a reduction in efficacy. |
| Leuprolide | Ularitide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy. |
| Goserelin | Ularitide may increase the excretion rate of Goserelin which could result in a lower serum level and potentially a reduction in efficacy. |
| Salmon calcitonin | Ularitide may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy. |
| Desmopressin | Ularitide may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy. |
| Aldesleukin | Ularitide may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy. |
| Daptomycin | Ularitide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
| Tositumomab | Ularitide may increase the excretion rate of Tositumomab which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyanocobalamin | Ularitide may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy. |
| Folic acid | Ularitide may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy. |
| Pyridoxine | Ularitide may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy. |
| Fluvoxamine | Ularitide may increase the excretion rate of Fluvoxamine which could result in a lower serum level and potentially a reduction in efficacy. |
| Baclofen | Ularitide may increase the excretion rate of Baclofen which could result in a lower serum level and potentially a reduction in efficacy. |
| Amphetamine | Ularitide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
| Cevimeline | Ularitide may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy. |
| Lorazepam | Ularitide may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy. |
| Carbidopa | Ularitide may increase the excretion rate of Carbidopa which could result in a lower serum level and potentially a reduction in efficacy. |
| Fluconazole | Ularitide may increase the excretion rate of Fluconazole which could result in a lower serum level and potentially a reduction in efficacy. |
| Oseltamivir | Ularitide may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydroxocobalamin | Ularitide may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy. |
| Reserpine | Ularitide may increase the excretion rate of Reserpine which could result in a lower serum level and potentially a reduction in efficacy. |
| Ticlopidine | Ularitide may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy. |
| Pantoprazole | Ularitide may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy. |
| Gadodiamide | Ularitide may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy. |
| Pregabalin | Ularitide may increase the excretion rate of Pregabalin which could result in a lower serum level and potentially a reduction in efficacy. |
| Temazepam | Ularitide may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy. |
| Milrinone | Ularitide may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy. |
| Butabarbital | Ularitide may increase the excretion rate of Butabarbital which could result in a lower serum level and potentially a reduction in efficacy. |
| Ranolazine | Ularitide may increase the excretion rate of Ranolazine which could result in a lower serum level and potentially a reduction in efficacy. |
| Benzatropine | Ularitide may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy. |
| Doxycycline | Ularitide may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy. |
| Carmustine | Ularitide may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy. |
| Metoprolol | Ularitide may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy. |
| Isradipine | Ularitide may increase the excretion rate of Isradipine which could result in a lower serum level and potentially a reduction in efficacy. |